Collectively, these findings suggest that auranofin decreased E2F1 and AR3 expression and is a potent inhibitor of cell growth in double drug-resistant prostate cancer cells both in vitro and in vivo. This evidence concerns the gene E2F1 and Familial prostate cancer.